Cargando…
Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association?
BACKGROUND: Diagnosis of multiple endocrine neoplasia type 1 (MEN1) is commonly based on clinical criteria, and confirmed by genetic testing. In patients without known MEN1-related germline mutations, the possibility of a casual association between two or more endocrine tumors cannot be excluded and...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543729/ https://www.ncbi.nlm.nih.gov/pubmed/23259638 http://dx.doi.org/10.1186/1471-2407-12-614 |
_version_ | 1782255694992375808 |
---|---|
author | Erdas, Enrico Aste, Nicola Pilloni, Luca Nicolosi, Angelo Licheri, Sergio Cappai, Antonello Mastinu, Marco Cetani, Filomena Pardi, Elena Mariotti, Stefano Pomata, Mariano |
author_facet | Erdas, Enrico Aste, Nicola Pilloni, Luca Nicolosi, Angelo Licheri, Sergio Cappai, Antonello Mastinu, Marco Cetani, Filomena Pardi, Elena Mariotti, Stefano Pomata, Mariano |
author_sort | Erdas, Enrico |
collection | PubMed |
description | BACKGROUND: Diagnosis of multiple endocrine neoplasia type 1 (MEN1) is commonly based on clinical criteria, and confirmed by genetic testing. In patients without known MEN1-related germline mutations, the possibility of a casual association between two or more endocrine tumors cannot be excluded and subsequent management may be difficult to plan. We describe a very uncommon case of functioning glucagonoma associated with primary hyperparathyroidism (pHPT) in which genetic testing failed to detect germline mutations of MEN-1 and other known genes responsible for MEN1. CASE PRESENTATION: The patient, a 65-year old woman, had been suffering for more than 1 year from weakness, progressive weight loss, angular cheilitis, glossitis and, more recently, skin rashes on the perineum, perioral skin and groin folds. After multidisciplinary investigations, functioning glucagonoma and asymptomatic pHPT were diagnosed and, since family history was negative, sporadic MEN1 was suspected. However, genetic testing revealed neither MEN-1 nor other gene mutations responsible for rarer cases of MEN1 (CDKN1B/p27 and other cyclin-dependent kinase inhibitor genes CDKN1A/p15, CDKN2C/p18, CDKN2B/p21). The patient underwent distal splenopancreatectomy and at the 4-month follow-up she showed complete remission of symptoms. Six months later, a thyroid nodule, suspected to be a malignant neoplasia, and two hyperfunctioning parathyroid glands were detected respectively by ultrasound with fine needle aspiration cytology and (99m)Tc-sestamibi scan with SPECT acquisition. Total thyroidectomy was performed, whereas selective parathyroidectomy was preferred to a more extensive procedure because the diagnosis of MEN1 was not supported by genetic analysis and intraoperative intact parathyroid hormone had revealed “adenoma-like” kinetics after the second parathyroid resection. Thirty-nine and 25 months after respectively the first and the second operation, the patient is well and shows no signs or symptoms of recurrence. CONCLUSIONS: Despite well-defined diagnostic criteria and guidelines, diagnosis of MEN1 can still be challenging. When diagnosis is doubtful, appropriate management may be difficult to establish. |
format | Online Article Text |
id | pubmed-3543729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35437292013-01-14 Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? Erdas, Enrico Aste, Nicola Pilloni, Luca Nicolosi, Angelo Licheri, Sergio Cappai, Antonello Mastinu, Marco Cetani, Filomena Pardi, Elena Mariotti, Stefano Pomata, Mariano BMC Cancer Case Report BACKGROUND: Diagnosis of multiple endocrine neoplasia type 1 (MEN1) is commonly based on clinical criteria, and confirmed by genetic testing. In patients without known MEN1-related germline mutations, the possibility of a casual association between two or more endocrine tumors cannot be excluded and subsequent management may be difficult to plan. We describe a very uncommon case of functioning glucagonoma associated with primary hyperparathyroidism (pHPT) in which genetic testing failed to detect germline mutations of MEN-1 and other known genes responsible for MEN1. CASE PRESENTATION: The patient, a 65-year old woman, had been suffering for more than 1 year from weakness, progressive weight loss, angular cheilitis, glossitis and, more recently, skin rashes on the perineum, perioral skin and groin folds. After multidisciplinary investigations, functioning glucagonoma and asymptomatic pHPT were diagnosed and, since family history was negative, sporadic MEN1 was suspected. However, genetic testing revealed neither MEN-1 nor other gene mutations responsible for rarer cases of MEN1 (CDKN1B/p27 and other cyclin-dependent kinase inhibitor genes CDKN1A/p15, CDKN2C/p18, CDKN2B/p21). The patient underwent distal splenopancreatectomy and at the 4-month follow-up she showed complete remission of symptoms. Six months later, a thyroid nodule, suspected to be a malignant neoplasia, and two hyperfunctioning parathyroid glands were detected respectively by ultrasound with fine needle aspiration cytology and (99m)Tc-sestamibi scan with SPECT acquisition. Total thyroidectomy was performed, whereas selective parathyroidectomy was preferred to a more extensive procedure because the diagnosis of MEN1 was not supported by genetic analysis and intraoperative intact parathyroid hormone had revealed “adenoma-like” kinetics after the second parathyroid resection. Thirty-nine and 25 months after respectively the first and the second operation, the patient is well and shows no signs or symptoms of recurrence. CONCLUSIONS: Despite well-defined diagnostic criteria and guidelines, diagnosis of MEN1 can still be challenging. When diagnosis is doubtful, appropriate management may be difficult to establish. BioMed Central 2012-12-22 /pmc/articles/PMC3543729/ /pubmed/23259638 http://dx.doi.org/10.1186/1471-2407-12-614 Text en Copyright ©2012 Erdas et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Erdas, Enrico Aste, Nicola Pilloni, Luca Nicolosi, Angelo Licheri, Sergio Cappai, Antonello Mastinu, Marco Cetani, Filomena Pardi, Elena Mariotti, Stefano Pomata, Mariano Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? |
title | Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? |
title_full | Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? |
title_fullStr | Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? |
title_full_unstemmed | Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? |
title_short | Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? |
title_sort | functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543729/ https://www.ncbi.nlm.nih.gov/pubmed/23259638 http://dx.doi.org/10.1186/1471-2407-12-614 |
work_keys_str_mv | AT erdasenrico functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT astenicola functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT pilloniluca functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT nicolosiangelo functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT licherisergio functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT cappaiantonello functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT mastinumarco functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT cetanifilomena functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT pardielena functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT mariottistefano functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation AT pomatamariano functioningglucagonomaassociatedwithprimaryhyperparathyroidismmultipleendocrineneoplasiatype1orincidentalassociation |